The global medical device market exceeded $800 billion in 2024 (BCC Research). The orthopedic segment alone — over $50 billion, growing at nearly 7% annually (Statista) — runs on a commercial infrastructure that would be unrecognizable to anyone outside the industry. Not because it is sophisticated, but because it is not.
Between the moment a surgical rep confirms a $50,000 hip case and the moment that revenue hits the manufacturer’s books, there’s a gap. Not a technology gap, exactly, and not a talent gap. A visibility gap — the space between what the field communicates and what the back office can act on. It might be the single most expensive unsolved problem in medical device distribution.
The anatomy of the gap
Here’s what it looks like at a mid-market orthopedic distributor doing $15–25 million in annual revenue. A 1099 rep closes a case. The case details arrive at headquarters via some combination of text message, email, a photo of a charge sheet taken under fluorescent lighting, and occasionally a voicemail left from the hospital parking lot. That information has to be translated into a purchase order, matched against contract pricing, entered into an ERP, reconciled with inventory records, and converted into an invoice.
If you want to see what that translation looks like at the individual case level — step by step, from the OR to the ERP — the charge sheet workflow is where the real complexity lives.
Three or four people on the ops team do this translation, spending 30–50% of their working hours on manual data reconciliation. At fully loaded costs of $55,000–$70,000 per head, the annual price tag runs $150,000–$220,000. For work that follows identical patterns almost every time.
Field reps don’t fare any better. Salesforce’s 2026 State of Sales report (cross-industry, not medtech-specific) put reps at 60% of their time on non-selling work, with 11% on manually entering data (Salesforce, 2026, p. 8). In medical device, that non-selling time isn’t tucked between meetings — it lands after each case, on top of the four manufacturer lines a top rep already carries in their head.
That doesn’t count what happens after. Industry-wide, healthcare billing disputes and denials cost an estimated $262 billion annually, roughly nine percent of all claims submitted (Change Healthcare). Initial denial rates have climbed to 11.8%, up from 10.2% in 2020 (Experian). Providers routinely fail to collect 2–5% of net patient revenue due to pricing errors and inefficient revenue cycle management (HIDA, 2020). For implantable device companies specifically, field inventory write-offs add another 2–5% of inventory value lost annually to expiration, loss, or damage (DHL Supply Chain, 2019). For a $20 million distributor, even conservative estimates put unbilled or incorrectly billed revenue leakage at $400,000–$1,000,000 per year. Cases completed, devices implanted, but never properly invoiced because something broke somewhere between the rep’s text and the ERP.
For a deeper look at how PO mismatches compound into billing disputes, account friction, and write-offs, see The PO Mess.
Why the gap persists
Medical device companies aren’t unsophisticated. They operate under FDA quality system regulations, manage complex supply chains, and navigate reimbursement environments that would humble most technology executives. The visibility gap endures because it works just well enough.
The operations staff who bridge this gap are, almost universally, excellent at their jobs. They know the reps, know the product catalogs, know which surgeon prefers which implant configuration. Their institutional knowledge is the connective tissue holding the commercial operation together. Leadership sees “operations headcount” on the P&L and assumes that is simply what operations costs.
It’s not. It’s the tax on a structural disconnect between two systems that were never designed to talk to each other. On one side: the unstructured, high-velocity communication layer of field sales — texts, emails, photos, verbal confirmations. On the other: the structured, rule-bound systems of record — ERPs, billing platforms, inventory databases. Between them, nothing but human memory and manual data entry.
The ERP vendors bear some responsibility here. Business Central, SAP, NetSuite — these systems were architected for manufacturing: production planning, procurement, inventory valuation, financial consolidation. They’re very good at what they were built to do. What they were not built to do is turn a photograph of a handwritten charge sheet into a clean purchase order. Companies spend $200,000–$400,000 on mid-market ERP implementations and then hire two additional full-time employees to bridge the gap the ERP was meant to close. Meanwhile, 70% of healthcare IT spending goes to maintaining these legacy systems rather than innovating beyond them (Andreessen Horowitz, 2021). The ERP isn’t the problem. The expectation that it should handle unstructured commercial workflows is.
The rep economy compounds the problem
The visibility gap gets especially expensive when you look at the independent sales channel. Medical device companies call their 1099 reps “our sales team.” They’re nothing of the sort. They’re independent contractors who carry a manufacturer’s product alongside four to nine competing lines and earn commissions, typically 10–30% depending on the product category, when cases close.
This is a distribution network, and distribution networks optimize for throughput, not loyalty. The rep’s daily calculus is straightforward: which manufacturer’s order gets processed without requiring three follow-up phone calls? Whose commission check arrives in seven days rather than sixty? Which company’s back office is invisible — in the best sense of the word?
Zimmer Biomet — the largest hip and knee implant manufacturer globally, with 27% combined market share (ORTHOWORLD, 2024) — recently announced that it will transition all 2,500 of its U.S. sales representatives to a fully dedicated, specialized salesforce by the end of 2027. CEO Ivan Tornos cited data showing competitors with dedicated salesforces are simply more productive (MedTech Dive, February 2026). I wrote about what this means for smaller manufacturers when the news broke. For small and mid-market manufacturers doing $5–50 million in revenue, building a dedicated direct salesforce isn’t viable. Their path to competitive advantage runs through the independent distribution channel. And in that channel, the manufacturer who eliminates friction wins.
The data backs this up. Distributors who compress case-to-payment cycles from the industry-standard 60–90 days to single digits report measurably higher rep engagement. It’s not complicated: when a rep carries ten lines and has to decide which product to mention first, operational ease is the tiebreaker. The manufacturer who pays fastest gets presented first, regardless of which product is technically superior.
What the numbers reveal
Deviceflow processes $1.25 million per month in medical device orders, growing at more than 30% month over month. The patterns in that transaction data are consistent to a degree that surprised us. Eighty percent of inbound orders follow one of five predictable patterns — same format, same fields, same sequence. Another 15–20% are minor variations requiring lightweight judgment. Only 5–10% involve genuine complexity: custom pricing, unusual configurations, new account setups.
Most distributors have their most experienced, most expensive operations staff spending the majority of their time on that first category. The work that requires zero judgment absorbs the most expensive labor. That’s not a criticism of the people. It’s a criticism of the systems that never separated the routine from the exceptional.
For a complete walkthrough of how this automation works across order types — bill-only, stocking, direct, consignment — see our order-to-cash automation guide.
The cost of invisibility
The visibility gap doesn’t appear as a line item on any distributor’s P&L. It’s not in cost of goods sold. It’s not explicitly in SG&A. It’s distributed across salary lines, software subscriptions, and an unknowable quantity of opportunity cost — the deals the team didn’t pursue because they were reconciling the previous week’s cases.
Nobody budgets for these costs because nobody sees them. They predate the current team, the current systems, the current leadership. They’re the water the fish swims in.
The question for every medical device distributor isn’t whether this gap exists — it does, and a candid audit of how your ops staff spend their time will prove it within a week. The question is whether the cost of bridging it manually is sustainable as order volumes grow, ASC procedure migration accelerates (outpatient joint replacements grew from 14% to 69% of Medicare cases between 2014 and 2022, per Curvo Research Network / Dexur), and margin pressure intensifies.
Have your operations lead track one number for the next month: the percentage of surgical cases where a charge sheet is submitted, processed, matched to a PO, and invoiced within 14 days. That number is the visibility gap, measured in dollars.
Sources:
- BCC Research, “Medical Devices: Technologies and Global Markets,” October 2024
- Andreessen Horowitz, “It’s Time to Build Healthtech Infrastructure,” 2021
- Change Healthcare claims denial analysis (via Healthcare Finance News)
- Curvo Labs / Orthopedic Network News, “2023 Hip and Knee Implant Review,” September 2023
- DHL Supply Chain, “Five Steps to a More Cost-Effective Implantable Device Supply Chain,” 2019
- Experian, “State of Claims Report,” 2025
- HIDA, “Improving Pricing Accuracy: Contract Communications Standards for the Healthcare Supply Chain,” 2020
- MedTech Dive, “Zimmer plans US salesforce reorganization,” February 2026
- ORTHOWORLD, “Orthopaedic Industry Annual Report,” 2024
- Statista, orthopedic device market data
- Salesforce, State of Sales, 7th Edition (2026), p. 8 — added in the May 31, 2026 verification pass to replace a fabricated Curvo Labs “30–40% rep admin coordination” claim that did not appear in the source PDF.